Cirsium Biosciences Advances Plant-Based AAV Manufacturing and Strengthens Quality Leadership

Cirsium Biosciences is advancing a plant-based platform for producing adeno-associated virus (AAV) vectors, emphasizing biological and operational mechanics rather than external deal milestones in this weekly summary of notable news. The company reiterated that visually stressed plant leaves can be the most productive, as energy is redirected from maintaining appearance to AAV expression in leaf tissue.

This focus on expression efficiency underscores Cirsium’s view that yield-relevant biology does not necessarily correlate with healthy-looking plants and may support scalable biomass production. If successfully translated into robust manufacturing performance, these insights could underpin lower cost-of-goods and stronger positioning in the AAV supply chain for gene therapy developers.

Operationally, Cirsium reported progress on proprietary “infiltrator” hardware, evolving from a 2022 manual device handling five plants to an automated system targeting batches of more than 100 plants. The company also showcased its broader AAV workflow from plant growth through post-infiltration expression and homogenized biomass, highlighting a defined, repeatable process.

In parallel, Cirsium is automating early-stage tray seeding to cut processing times from hours to minutes while maintaining precision. These automation efforts are intended to improve throughput, consistency, and scalability, potentially reducing labor intensity as production volumes rise and supporting more competitive manufacturing economics.

To match its technical scale-up, the company strengthened its leadership bench in quality, operations, and facilities, including a Senior Director of Quality Assurance with over 35 years of industry experience and a Senior Director of Operations overseeing operational, financial, and technology infrastructure. Additional hires, such as a Facility Manager and Lab Aide, are aimed at supporting vertical farms, integrated processes, and routine lab workflows.

Cirsium also highlighted the experience of internal scientific staff, including Scientist I Matthew Kohls, whose three decades in life sciences underscore the depth of technical expertise behind the platform. Overall, the week reflected infrastructure- and process-focused progress designed to de-risk scale-up and prepare Cirsium Biosciences for eventual commercial opportunities in plant-based AAV manufacturing, rather than immediate external inflection points.